Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.55 |
| ▸ | PTPRC | P08575 | 1/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.55 |
| ▸ | PTPRA | P18433 | 1/20 | 0.55 |
| ▸ | PTPRB | P23467 | 1/20 | 0.55 |
| ▸ | PTPRE | P23469 | 1/20 | 0.55 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.55 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.49 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.49 |
| ▸ | TPMT | P51580 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21592068 | 0.87 | PTPRC (0.49) | PTPN1PTPRCPTPN2PTPRAPTPRB | |
| SCHEMBL9117052 | 0.87 | PTPRC (0.49) | PTPN1PTPRCPTPN2PTPRAPTPRB | |
| SCHEMBL1277864 | 0.83 | PTPRC (0.53) | PTPN1PTPRCPTPN2PTPRAPTPRB | |
| SCHEMBL588405 | 0.83 | PTPN1 (0.48) | PTPN1PTPRCPTPN2PTPRAPTPRB | |
| SCHEMBL27178328 | 0.82 | MCL1 (0.50) | PTPN1TPMTALDH1A1ALOX15CYP1A2 | |
| SCHEMBL21695485 | 0.82 | PTPRC (0.49) | PTPN1PTPRCPTPN2PTPRAPTPRB | |
| SCHEMBL20757754 | 0.82 | AKR1C3 (0.62) | PTPN1PTPRCPTPN2PTPRAPTPRB | |
| SCHEMBL29662013 | 0.81 | CA1 (0.61) | PTPN1PTPRCPTPN2PTPRAPTPRB | |
| SCHEMBL129664 | 0.81 | CA1 (0.61) | PTPN1PTPRCPTPN2PTPRAPTPRB | |
| SCHEMBL980376 | 0.81 | ALDH1A1 (0.61) | PTPN1PTPRCPTPN2PTPRAPTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5081291-A | Process for manufacture of 3,3',4,4'-biphenyltetracarboxylic acid | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-01-14 | — | — | US | claimed |
| EP-4683934-A1 | SYSTEM | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2026-01-28 | — | — | EP | disclosed |
| WO-2025100238-A1 | EPOXY COMPOUND AND USE THEREOF | 四国化成工業株式会社 | 2025-05-15 | — | — | WO | disclosed |
| US-20250136620-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2024194645-A1 | SYSTEM | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-09-26 | — | — | WO | disclosed |
| CN-117897388-A | BTK protein degradation agent | 广州麓鹏制药有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20240058457-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2024-02-22 | — | — | US | disclosed |
| EP-4263552-A1 | BTK DEGRADER | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023137225-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| EP-3918647-B1 | PHOTOELECTRIC CONVERSION ELEMENT, DEVICE, AND POWER SUPPLY MODULE | RICOH CO LTD (JP) | 2023-03-08 | — | — | EP | disclosed |
| CN-1816527-A | Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin | FIBROGEN INC (US) | 2006-08-09 | — | — | CN | disclosed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-5672750-A | Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride | EASTMAN CHEMICAL COMPANY (US) | 1997-09-30 | — | — | US | disclosed |
| WO-1992005139-A1 | PROCESS FOR MANUFACTURE OF 3,3',4,4'-BIPHENYLTETRACARBOXYLIC ACID | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-04-02 | — | — | WO | disclosed |
| US-5081291-A | Process for manufacture of 3,3',4,4'-biphenyltetracarboxylic acid | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-01-14 | — | — | US | disclosed |
| US-4727185-A | Process for preparation of 3,3',4,4'-biphenyltetracarboxylic acid salts | HITACHI, LTD. (JP) | 1988-02-23 | — | — | US | disclosed |
| US-4456452-A | Process for bleaching textiles and for combating microorganisms with sulphonated phthalocyanine carrying halogen or pseudohalogen substituents as photoactivator | CIBA-GEIGY CORPORATION (US) | 1984-06-26 | — | — | US | disclosed |
| US-4394125-A | Process for bleaching textiles and for combating micro-organisms with sulfonated phthalocyanine of aluminum or zinc and containing halogen or cyano substituents as photoactivator | CIBA-GEIGY CORPORATION (US) | 1983-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058457-A1 | BTK DEGRADER | BTK, LYN, SYK | PTPN1 40/4885PTPRC 97/4885PTPN2 106/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | PTPN1 3493/4885PTPRC 1255/4885PTPN2 2980/4885 |
| US-20250136620-A1 | BTK DEGRADER | BTK, CBL, LYN | PTPN1 159/4885PTPRC 207/4885PTPN2 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.